These results are in accordance with the ones obtained from the tool UALCAN, where a higher expression of TCN1 is observed in those patients diagnosed with breast invasive carcinoma and with a higher overall survival (p = 0.042) (Figure 7). Here, TCN1 is linked to invasive breast carcinoma.